Shares of RAPT Therapeutics shot higher after the biopharmaceutical company said it would be acquired by drugmaker GSK for around $2.2 billion. The stock climbed 64% to $57.41 in premarket trading ...
GSK shares rose to the top of the FTSE 100 leader board after the drugmaker raised its 2025 guidance on the back of a strong third-quarter performance. The earnings were the last to be presented by ...
LONDON (Reuters) -GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit growth, lifting the British company's shares by nearly 7% to ...
When BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some financial analysts said the buyout amounted to an out-of-court settlement of ...
GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. He joined GSK in 2017 and is currently Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback